Shield Therapeutics

(STX)
Sector: Pharmaceuticals & Biotechnology
2.82p
-0.03p -1.05
Last updated: 11:50:29

Company News Headlines

Date Time Headline Source
21/11/2024 07:00 Business Update RNS
29/10/2024 07:00 Q3 Trading Update RNS
25/09/2024 07:00 Results from Phase 3 paediatric study RNS
04/09/2024 07:00 Interim results RNS
27/08/2024 07:00 ACCRUFeR® Approved by Health Canada RNS
14/08/2024 07:00 Notice of interim results RNS
24/07/2024 07:01 Unaudited Q2 2024 Trading Update RNS
24/07/2024 07:00 Directorate Change RNS
03/07/2024 07:00 $5.7m Milestone Monetization Agreement with AOP RNS
20/06/2024 16:25 Results of 2024 Annual General Meeting RNS
28/05/2024 07:00 New Drug Application for Accrufer® in South Korea RNS
10/05/2024 15:30 Audited results for the year ended 31 Dec 2023 RNS
30/04/2024 07:00 Business Update for Q1 2024 RNS
16/04/2024 07:00 Notice of Results RNS
21/02/2024 07:00 Unaudited Full Year Trading Update RNS
09/01/2024 07:00 Appointment of new Chief Financial Officer RNS
07/12/2023 07:00 Q3 2023 U.S. Commercial Highlights RNS
27/11/2023 17:24 PDMR Transaction Notification RNS
15/11/2023 07:30 Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team EQS Group
12/10/2023 07:00 Chief Financial Officer Transition RNS
03/10/2023 15:00 Result of REX Retail Offer RNS
03/10/2023 07:00 Completion of SWK Financing RNS
03/10/2023 07:00 Block listing Interim Return RNS
28/09/2023 12:50 Successful completion of US$6.1m Equity Fundraise RNS
28/09/2023 07:02 REX Retail Offer RNS
28/09/2023 07:01 $20m secured debt facility &proposed equity raise RNS
28/09/2023 07:00 Interim results update and business update RNS
06/09/2023 07:00 Notice of Results and Change in reporting currency RNS
25/07/2023 09:45 Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering EQS Group
24/07/2023 14:27 Holding(s) in Company RNS
20/07/2023 07:00 Business Update and U.S. Q2 2023 Highlights RNS
28/06/2023 17:30 Results of 2023 Annual General Meeting RNS
16/06/2023 12:00 Form 8.5 (EPT/RI) - Shield Therapeutics Plc RNS
15/06/2023 16:35 Lapse of Offer RNS
15/06/2023 12:00 Form 8.5 (EPT/RI) - Shield Therapeutics Plc RNS
15/06/2023 07:00 Acceptance Level Update RNS
14/06/2023 12:00 Form 8.5 (EPT/RI) - Shield Therapeutics Plc RNS
14/06/2023 07:00 Acceptance Level Update RNS
13/06/2023 12:00 Form 8.5 (EPT/RI) - Shield Therapeutics Plc RNS
13/06/2023 07:00 Acceptance Level Update RNS
12/06/2023 12:00 Form 8.5 (EPT/RI) - Shield Therapeutics Plc RNS
12/06/2023 07:00 Acceptance Level Update RNS
09/06/2023 12:00 Form 8.5 (EPT/RI) - Shield Therapeutics Plc RNS
09/06/2023 07:00 Acceptance Level Update RNS
08/06/2023 12:31 Form 8.3 - Shield Therapeutics PLC (amendment) RNS
08/06/2023 12:00 Form 8.5 (EPT/RI) - Shield Therapeutics Plc RNS
08/06/2023 07:00 Acceptance Level Update RNS
07/06/2023 12:00 Form 8.5 (EPT/RI) - Shield Therapeutics Plc RNS
06/06/2023 12:00 Form 8.5 (EPT/RI) - Shield Therapeutics Plc RNS
06/06/2023 10:10 Grant of share options to the CEO RNS